ACS Biomaterials Science & Engineering
Cure8 research brief
Why This Matters
This work describes a novel engineered probiotic designed to survive the gastrointestinal tract and act specifically at inflamed colitis sites, which could lead to new targeted therapies for IBD if validated in humans.
Who Should Pay Attention
Researchers working on microbiome-based therapies, biomaterials and drug-delivery for IBD; translational clinicians interested in experimental IBD treatments.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports an engineering approach that assembles quercetin, lipoic acid, and phosphatidylserine into nanoparticles (QL@PS NPs) and coats thiolated Lactobacillus rhamnosus to create “nanoarmored” probiotics (LAB@NPs).
The abstract describes in vitro antioxidant and anti-inflammatory activity, improved uptake by macrophages, and protection of the probiotic from gastrointestinal and oxidative damage. The authors report lesion-specific effects and improved outcomes in mouse colitis models (less colon shortening, reduced inflammation, and less tissue damage).
The article is presented as an experimental, preclinical biomaterials study rather than a clinical trial.
Keep In Mind
The article is a basic-science, preclinical study reported in ACS Biomaterials Science & Engineering with abstract-level results. Animal-model findings do not equal clinical benefit in people; further safety and clinical trials would be needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACS Biomaterials Science & Engineering
PublisherAmerican Chemical Society (ACS)
AuthorsWen Li, Siyuan Yuan, Hongjing Wu +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 6, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: National Natural Science Foundation of China, award 22205008; National Natural Science Foundation of China, award 22274003; Natural Science Foundation of Anhui Province, award 2008085QB76; Higher Education Discipline Innovation Project, award D26004
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Quaternized chitosan-based double-network hydrogel for oral precise delivery of Sinapic acid in ulcerative colitis therapy.
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...